

**BOOK BY OCTOBER 25 TO
SAVE UP TO €900**

February 25-27, 2020 | Vienna, Austria

www.ras-europe.com



RAS-Targeted Drug Discovery Europe

Finally Drug the "UnDruggable" RAS

**Advance Novel Target Site Discovery,
Improve Drug-Like Properties &
Accelerate the Translation of Robust
Therapeutic Strategies to Finally
Target RAS Mutants Successfully**

Expert Speakers Include:



Julian Downward
Associate Research
Director
Francis Crick Institute



Darryl McConnell
Senior Vice President
& Research Site Head
Austria
Boehringer Ingelheim



Dwight V. Nissley
Director, Cancer Research
Technology Program; NCI
RAS Initiative
**Frederick National
Laboratory for Cancer
Research**



Laurent Debussche
Vice President, Global
Head Molecular
Oncology Research
Therapeutic Area
Sanofi R&D



Steve Kelsey
President, Research &
Development
Revolution Medicines



Stig Hansen
Chief Executive Officer
Carmot Therapeutics



Grahame McKenzie
Chief Scientific Officer
PhoreMost



Juan J. Perez
Chief Scientific Officer
Allinky Biopharma



Sreesha P. Srinivasa
Senior Vice President
Oblique Therapeutics

The Only European Industry-Dedicated Meeting Focused On Drugging The “~~U~~ndruggable” RAS

Advance Novel Target Site Discovery, Improve Drug-Like Properties & Accelerate the Translation of Robust Therapeutic Strategies to Finally Target RAS Mutants Successfully

After three decades of trial and error to target the driver of 30% of all diagnosed cancers, scientists are finally making meaningful clinical progression to target the cancer master switch, the RAS family of proteins.

The **RAS- Targeted Drug Discovery Summit Europe** is **the only industry and translational focused platform** dedicated to bringing you innovative anti-RAS drug discovery science, capturing the most pioneering data, thought-provoking insights and practical lessons learned, enabling you to **maximise the clinical therapeutic window of your anti-RAS candidate**.

Uniting the leading minds from large pharma, biotech and academia, this summit will help you **advance novel target site discovery, improve drug-like properties** and **accelerate the translation of potent and mutation-specific RAS targeted therapeutic strategies into human clinical trials**.

With numerous approaches emerging that demonstrate genuinely viable efficacy in targeting the RAS family of proteins, join the **RAS- Targeted Drug Discovery Summit Europe** to gain first-hand insights on the challenges and strategies to robustly translate promising anti-RAS therapies into the clinic.

What are our speakers looking forward to?


“I find it an exciting opportunity to share the recent developments in RAS research and synergise the efforts to target this important oncogene for the betterment of millions of patients”

Krishnaraj Rajalingam,
Heisenberg Professor of Cell
Biology, Cell Biology Unit,
**University Medical Center
Mainz**

“This event will bring together key opinion leaders from both academia and drug discovery in order to deliver a truly translational meeting focused on how best to tackle oncogenic RAS”

Grahame McKenzie, Chief
Scientific Officer, **PhoreMost**

Why Attend the RAS- Targeted Drug Discovery Summit Europe?



Benchmark against the latest strategies to finally drug the “undruggable” RAS family of proteins with insights from **Boehringer Ingelheim, Sanofi & Bayer**



Leverage the latest *in vitro* and *in vivo* data to optimise your anti-RAS drug discovery approach with insights from **Francis Crick Institute, NCI RAS Initiative & Spanish National Cancer Research Center**



Enable your RAS drug discovery efforts by harnessing the latest tools and technologies with insights from **Carmot Therapeutics, Phormost & Allinky Biopharma**



Overcome selectivity, potency and drug-like properties with insights from **Oblique Therapeutics, Elicio Therapeutics & Revolution Medicines**



Gain strategic and data-driven awareness of the translational and clinical outcomes of targeting RAS family of proteins with insights from **Onconova Therapeutics, Targovax & The Christie NHS Foundation Trust**

YOUR EXPERT SPEAKERS



Julian Downward
Associate Research
Director
**Francis Crick
Institute**



Mariano Barbacid
AXA.CNIO Professor of
Molecular Oncology
**CNIO (Spanish
National Cancer
Research Center)**



Darryl McConnell
Senior Vice President
& Research Site Head
Austria
Boehringer Ingelheim



Dwight V. Nissley
Director, Cancer Research
Technology Program; NCI
RAS Initiative
**Frederick National
Laboratory for Cancer
Research**



Laurent Debussche
Vice President, Global
Head Molecular
Oncology Research
Therapeutic Area
Sanofi R&D



Steve Kelsey
President, Research &
Development
Revolution Medicines



Stig Hansen
Chief Executive Officer
Carmot Therapeutics



Grahame McKenzie
Chief Scientific Officer
PhoreMost



Juan J. Perez
Chief Scientific Officer
Allinky Biopharma



Peter DeMuth
Vice President of
Research
Elicio Therapeutics



Sreesha P. Srinivasa
Senior Vice President
Oblique Therapeutics



Bert Klebl
Managing Director &
Chief Scientific Officer
**Lead Discovery
Center**



**Krishnaraj
Rajalingam**
Heisenberg Professor
of Cell Biology, Cell
Biology Unit
**University Medical
Center Mainz**



Steven M. Fruchtmann
President & Chief
Executive Officer
**Onconova
Therapeutics**



Erik D. Wiklund
Chief Business Officer
Targovax



Colin Lindsay
Clinical Senior Lecturer,
The University of
Manchester; Medical
Oncology Consultant
**The Christie NHS
Foundation Trust**



Roman Hillig
Senior Scientist
Bayer



Michael Gmachl
Principal Scientist,
Regional Center
Austria
Boehringer Ingelheim



Daniel Abankwa
Professor of Cellular
Tumour Biology
**University of
Luxembourg**



Angeliki Malliri
Senior Group Leader &
Professor of Cell Biology,
Cancer Research UK
Manchester Institute
**The University of
Manchester**



Sara Mainardi
Senior Postdoctoral
Researcher
**Netherlands Cancer
Institute**



Tatu Pantsar
Marie Skłodowska,
Curie Fellow
**University of
Tübingen**



Nicolas Bery
Postdoctoral Research
Scientist
University of Oxford

PRE-CONFERENCE WORKSHOP

TUESDAY 25 FEBRUARY

14.00 - 16.30

Working Towards a Translational Programme in RAS Targeting

In 2019, the first reports of clinical efficacy using direct inhibitors of KRAS G12C were released, already showing great promise for the future implementation of these drugs in the cancer clinic. In parallel, current clinical trial evidence suggests that lung cancers driven by KRAS mutation are also vulnerable to treatment with immune checkpoint inhibitors.

The aim of this workshop is to share our experience of pursuing a RAS translational programme in the clinic across two Cancer Research UK institutes. The first part of the workshop will examine what constitutes a successful biomarker for clinical roll-out, drawing parallels with the progress achieved in other molecular sub-sets of cancer where established treatment approaches are still improving. The second part of the workshop will explore what delegates consider to be the optimal cell line and animal models for study of the MAP kinase pathway and its immunotherapeutic vulnerabilities.

Topics to be covered:

- How are biomarkers successfully translated for the clinical application of small molecules and immuno-therapy?
- What lessons can be taken from other examples of successful small molecule drug targeting in cancer, such as EGFR mutation or ALK re-arrangement?
- How is next generation sequencing being implemented in hospitals?
- What are the optimal tissue culture models for studying RAS-driven cancer?
- What are the optimal animal models for studying RAS-driven cancer?

Workshop Leaders



Angeliki Malliri

Senior Group Leader
& Professor of Cell
Biology, Cancer
Research UK
Manchester Institute
**The University of
Manchester**

Dr. Angeliki Malliri completed her bachelors degree in Biology in the University of Patras, Greece and obtained her PhD from the University of Crete, Greece. She worked as a postdoctoral scientist in the Beatson Institute for Cancer Research, Glasgow, UK and the Netherlands Cancer Institute in Amsterdam. She established her independent research group in 2004 in Cancer Research UK Manchester Institute, UK. The focus of her current research is the role of the small GTPase RAC and its regulators in lung tumour formation and progression, including lung tumourigenesis initiated by mutant KRAS. They have also recently instigated a program of research addressing KRAS-mutant isoform selective functions in lung cancer development.



Colin Lindsay

Clinical Senior
Lecturer, The
University of
Manchester;
Medical Oncology
Consultant
**The Christie NHS
Foundation Trust**

Dr. Colin Lindsay is a Clinical Senior Lecturer in medical oncology, with his time divided 50/50 between research and the clinic. Originally, he trained at the CRUK Beatson Institute and Cancer Centre in Glasgow, where he completed a PhD studying genetically-modified mouse models of RAS- and RAF-driven melanoma. Following that he shifted focus to lung cancer through involvement with the CRUK Stratified Medicine Programme, as well as a two year ESMO translational fellowship at the Gustave Roussy Institute in Villejuif, France. His main interests are 1) the implementation of effective treatment strategies for cancers driven by the MAPK pathway, and 2) successful and efficient translation of genomic results for optimal clinical gain.

CONFERENCE DAY ONE

WEDNESDAY 26 FEBRUARY

	8.00 Registration & Networking Coffee
	8.50 Chair's Opening Remarks
Delivering on the Vision of Drugging the Undruggable RAS Oncogene	
Julian Downward Associate Research Director Francis Crick Institute	9.00 Combination Approaches to the Use of G12C KRAS Inhibitors - KRAS G12C inhibitors have proved effective on many G12C KRAS mutant tumour in vitro, in vivo and in clinical trials, but acquired and pre-existing resistance is a problem - Several approaches have been taken to establish how best to combine these drugs for more effective treatment of KRAS G12C mutant cancers and minimisation of resistance - The response of KRAS G12C mutant lung tumour with these inhibitors profoundly alters the tumour immune microenvironment, allowing ingress of various effector immune cells: studying the phenotype of these cells suggests optimal combinations between KRAS G12C inhibitors and immunotherapies
Dwight V. Nissley Director, Cancer Research Technology Program; NCI RAS Initiative Frederick National Laboratory for Cancer Research	9.30 Targeting KRAS-Driven Oncogenic Signalling - Inhibition of KRAS using small molecule inhibitors - KRAS and activation of signaling at the plasma membrane - KRAS complexes
Darryl McConnell Senior Vice President & Research Site Head Austria Boehringer Ingelheim	10.00 Drugging the Other KRAS Mutants - Boehringer Ingelheim is taking a systematic approach to discovering drugs for all KRAS mutants - The potential approaches to drugging KRAS beyond G12C with small molecules will be discussed - Highlights from some of Boehringer Ingelheim's KRAS programs will be presented
	10.30 Speed Networking & Morning Refreshments
Optimising Robust Strategies to Target the Cancer Master Oncogene	
Mariano Barbacid AXA.CNIO Professor of Molecular Oncology CNIO (Spanish National Cancer Research Center)	11.30 Targeting KRAS Singling - Description of a genetically engineered KRAS/TP53-driven mouse lung and pancreatic tumour models driven by the KRAS G12C mutation - Targeting the canonical MAPK pathway is unacceptable toxic: Genetic evidence - RAF1 as a "non-toxic" key mediator of KRAS oncogenic signalling
Laurent Debussche Vice President, Global Head Molecular Oncology Research Therapeutic Area Sanofi R&D	12.00 RAS Protein Flexibility & How to Target Cryptic Pockets to Drug the Undruggable Master Oncogene - RAS is a very flexible protein without any apparent druggable pocket which has resisted three decades of efforts to drug it - Cryptic or induced pockets can be identified in addition to so-called SII pocket - DNA-encoded library approach is a powerful approach to drug cryptic pockets such as SII pocket
Steve Kelsey President, Research & Development Revolution Medicines	12.30 Strategies to Inhibit RAS-Driven Cancers - SHP2 inhibition - Combination strategies - Tri-complex small molecule inhibitors of the oncogenic, GTP-bound (ON) form of KRAS
	13.00 Networking Lunch

Accelerating Anti-RAS Drug Discovery Through New Tools & Technologies

Stig Hansen Chief Executive Officer Carmot Therapeutics	14.00 Chemotype Evolution: Accelerating Drug Discovery for Challenging Targets - Chemotype Evolution (CE) is a versatile technology that accelerates drug discovery for challenging targets - Using this technology, Carmot has discovered novel covalent KRAS G12C inhibitors - Covalent CE can be leveraged to identify new treatments for KRAS-driven cancers
Grahame Mckenzie Chief Scientific Officer PhoreMost	14.30 Revealing New RAS Vulnerabilities with Protein Interference (PROTEINi) - Oncogenic RAS remains largely undrugged - PROTEINi identifies new targets which are synthetic lethal with RAS - PhoreMost's SITESEEKER platform provides key pharmacophoric information about how to go about drugging these targets
Juan J. Perez Chief Scientific Officer Allinky Biopharma	15.00 Design of Small Molecule Allosteric Inhibitors of KRAS - We will present the in vitro and in vivo results of a series of orally available small molecules that were designed following an in silico approach - These novel therapeutics bind onto an allosteric site of KRAS
	15.30 Afternoon Refreshments & Poster Session

Empowering Potent Anti-RAS Drug Discovery with Novel Assays & Strategies

Peter DeMuth Vice President of Research Elicio Therapeutics	16.00 Targeting the Lymph Nodes to Enhance Mutant KRAS-Specific Vaccine Responses - Review of Elicio's lymph node targeting AMP vaccination platform - Data showing vaccine-induction of potent mKRAS-specific T cell responses - Review of Elicio mKRAS clinical development program
Sreesha P. Srinivasa Senior Vice President Oblique Therapeutics	16.30 Generation & Characterisation of Antibodies Targeting Mutant KRAS Proteins - Generation of selective antibodies - Biochemical characterisation - Functional characterisation in wild type and mutant cancer cell lines
Bert Klebl Managing Director & Chief Scientific Officer Lead Discovery Center	17.00 Rush or Crash – “High” Ways or Dead Ends to Tackle RAS Small molecule RAS modulation: - RAS shuttling from endomembranes to the plasma membrane - KRAS stabilisation - KRAS wild type vs. mutant inhibition
Krishnaraj Rajalingam Heisenberg Professor of Cell Biology, Cell Biology Unit University Medical Center Mainz	17.30 A Subset of Flavaglines Inhibit KRAS Oncogene Activation - Novel assays to measure KRAS activation in cells - Identification of flavagline derivatives as potent KRAS inhibitors - Mechanisms and in vivo effects
	18.00 Chair's Closing Remarks & End of Day One

CONFERENCE DAY TWO

THURSDAY 27 FEBRUARY

8.30 Coffee & Networking

8.55 Chair's Opening Remarks

Targeting the Previously Undruggable: Translational & Clinical Perspective of Targeting RAS

Steven M. Fruchtmann
President & Chief
Executive Officer
**Onconova
Therapeutics**

9.00 Rigosertib is a Unique Small Molecule RAS Antagonist: Scientific & Clinical Studies

- Rigosertib targets RAS as a RAS mimetic interacting with its effector proteins
- Role of genetic and RAS pathway mutations in MDS
- An update of RAS in the clinic

Erik D. Wiklund
Chief Business Officer
Targovax

9.30 Vaccinating Against Mutant RAS – Results from TG01 Phase I/II Trial

- Results from 32-patient TG01 trial in resected pancreatic cancer
- Robust immune responses demonstrated against KRAS
- Overview of clinical and molecular outcomes

Colin Lindsay
Clinical Senior
Lecturer, The
University of
Manchester; Medical
Oncology Consultant
**The Christie NHS
Foundation Trust**

10.00 RAS Mutation: Being Precise in Precision Medicine

- Clinical and translational perspective on previous clinical trial disappointments with RAS targeting
- Looking towards immunotherapy combinations with small molecules in the lung cancer landscape
- Examination of whole genome/exome sequencing results from RAS mutant lung cancer

10.30 Morning Refreshments & Networking

Enabling Structure Guided & Selective Targeting of RAS Proteins

Roman Hillig
Senior Scientist
Bayer

11.00 Disruption of the RAS-SOS1 Interaction – Enabling Lead Discovery by a Combination of High-Throughput & Fragment Screening

- Combination of high-throughput & fragment screening enabled a new approach to target KRAS
- Structure-guided optimisation of potent and selective SOS1 inhibitors
- Cellular data support a possible combination potential of SOS1 inhibitors with covalent inhibitors of KRAS^{G12C}

Michael Gmachl
Principal Scientist,
Regional Center
Austria
**Boehringer
Ingelheim**

11.30 Discovery of BI-3406: A Potent & Selective SOS1: KRAS Inhibitor Opens a New Approach for Treating KRAS-Driven Tumours

- BI 3406 selectively binds to SOS1 and blocks the interaction with KRAS, irrespective of the KRAS mutation
- BI 3406 causes RAS GTP and pERK reduction and inhibits cell growth of KRAS mutated cell lines, carrying most of the typical KRAS mutations (i.e. G12D, G12V, G13D and others)
- BI 3406, when administered orally to tumour bearing mice, causes a dose dependent tumour static effect that can be converted into regressions when combined with MEK1 inhibition

Daniel Abankwa
Professor of Cellular
Tumour Biology
**University of
Luxembourg**

12.00 Drug Development Against KRAS Surrogate Targets

- Selective targeting of KRAS, but not H-RAS may specifically eliminate cancer stem cells (CSC)
- To this end, we developed novel inhibitors against PDE6D/ PDEdelta, a surrogate target of KRAS, which realise KRAS selectivity and thus anti-CSC activity
- Secondly, we describe a new mechanism of how Hsp90 inhibition likewise selectively targets KRAS; novel small-molecule Hsp90/Cdc37 protein-protein interface inhibitors are presented

Angeliki Malliri Senior Group Leader & Professor of Cell Biology, Cancer Research UK Manchester Institute The University of Manchester	12.30 The Role of the Activator of the Small GTPase RAC, TIAM1, in Mutant KRAS Driven Lung Adenocarcinomas • The small GTPase RAC has been shown to be required for KRAS-induced lung tumourigenesis • TIAM1, one of the RAC activators, is a RAS effector protein • The role of TIAM1 in the formation and progression of mutant KRAS-driven lung adenocarcinoma and its mechanism of action will be discussed
	13.00 Networking Lunch
Advancing Discovery & Characterisation of Novel Anti-RAS Strategies	
Sara Mainardi Senior Postdoctoral Researcher Netherlands Cancer Institute	14.00 Targeting RAS-Driven Tumour by Exploiting Vulnerabilities in the RAS Network • Mutant RAS is still dependent from upstream stimulation • Inhibition of upstream RAS stimulation (SHP2) confers sensitivity to downstream (MEK and ERK) inhibitors • Triple vertical targeting of the MAPK pathway enhances anti-Tumour efficacy and prevents resistance
Tatu Patsar Marie Skłodowska, Curie Fellow University of Tübingen	14.30 RAS Conformational Dynamics & Its Influence on RAS Drug Discovery • Why is it important to understand RAS dynamics? • What do we really understand of RAS dynamics? • How does RAS dynamics impact on drugging RAS?
Nicolas Bery Postdoctoral Research Scientist University of Oxford	15.00 Targeting Mutant KRAS Tumours with a Functionalised Anti-KRAS Macromolecule • Development of biosensors to characterise anti-RAS small-molecules and macromolecules (i.e. intracellular single domains) • Discovery and characterisation of novel KRAS-specific macromolecules • The specific inhibition of mutant KRAS tumours by functionalised macromolecules
	15.30 Chair's Closing Remarks & Close of RAS- Targeted Drug Discovery Summit Europe

■ The recent RAS- Targeted Drug Discovery meeting in Boston was an exciting and educational opportunity bringing together basic and clinical scientists studying the RAS pathway and the clinical implications of the dysregulation of this pathway. Scientists presented their concepts on how they believe the pathway; until recently difficult to influence; can now be modulated. And how this progress has translated into clinical trials in various diseases driven by mutations of that pathway ■

**Steven M. Fruchtman, President & Chief Executive Officer,
Onconova Therapeutics**

WHY ARE OUR EXPERT SPEAKERS GETTING INVOLVED AT THE SUMMIT?

“The field of RAS inhibitory drugs has exploded in the last few years and this meeting will be an excellent opportunity to catch up on the latest developments in this fast moving area”



Julian Downward
Associate Research
Director
**Francis Crick
Institute**

“The long-awaited breakthroughs in targeting mutant RAS are now with us, and research and development in the RAS field is advancing rapidly. This meeting will bring together top researchers in the field. Attendance and participation will be critical to stay with the field”



Steve Kelsey
President, Research &
Development
Revolution Medicines

“I am hoping that this event will bring together opinion leaders from both academia and drug discovery in order to deliver a truly translational meeting focused on how best to tackle oncogenic RAS”



Grahame McKenzie
Chief Scientific
Officer
PhoreMost

“This meeting provides a great opportunity to discuss new approaches to this rapidly advancing area in cancer therapeutics”



Stig Hansen
Chief Executive Officer
Carmot Therapeutics

“Targeting oncogenic KRAS signalling is one of the most exciting challenges in cancer biology. Recent clinical trials with KRAS G12C specific inhibitors open up a first glimpse on the potential of targeting oncogenic KRAS in general. Networking, exchange of ideas and experiences in the KRAS field is one of the major values of this meeting”



Michael Gmachl
Principal Scientist, Regional
Center Austria
Boehringer Ingelheim

BECOME A COMMERCIAL PARTNER



60+

ATTENDEES



7+

HOURS OF DEDICATED NETWORKING



1

INTERACTIVE WORKSHOP



23+

REAL WORLD CASE STUDIES



Benefit from Market Intelligence

Drugging the previously undruggable RAS targets creates tremendous opportunity to address the current unmet clinical need. Hear how and where pharmaceutical giants are looking for services and solutions to facilitate their R&D platforms and match your solutions accordingly



Raise Brand Awareness

Benefit from pre and post conference exposure to our drug discovery KOL community and increase market share through unique branding formats. Also, differentiate your discovery, pre-clinical and translational services from other solution providers



Position Yourself as an Industry Expert

With the emergence of biotech companies focused on developing mutant-targeted RAS therapies, followed by interest shown from large pharma and investors, this meeting is a dedicated platform to put your independent expertise in front of the key decision-makers in the field



Meet & Network with Industry Pioneers

With a room full of drug developers looking to see how they can effectively translate their exciting early discovery efforts into safe and effective therapeutics, meet prospective clients during speed networking breaks, 1-2-1 meetings and more informal networking receptions



Generate Commercial Collaborations

Make sure your hottest prospects are in the room and part of the discussion, by having a wishlist of your choice contacted in advance of the event

SENIORITY




Director & C-Level: 45%

Scientists & Team Leaders: 25%

Other: 20%

COMPANY BY TYPE



*Based on audience breakdown from RAS- Targeted Drug Discovery Boston 2019

BECOME A PARTNER



Bashir Langhi

Partnerships Director

E: sponsor@hansonwade.com

T: +44 (0)203 141 8797

READY TO REGISTER?

3 EASY WAYS TO BOOK



www.ras-europe.com



Tel: +44 203 141 8700



Email: register@hansonwade.com



SAVE valuable time and resources by learning how the leading companies in the space are advancing their anti-RAS strategies



GAIN first-hand insights on challenges and strategies on how to robustly translate promising direct anti-RAS therapies into clinical development and increase your success rate



FORM lasting connections by engaging directly with colleagues from the leading pharma and biotech companies actively developing anti-RAS therapies and seeking the best solutions, in an intimate environment

SECURE YOUR PLACE

Industry Pricing*	Register & Pay By Friday 25 October (Save Up To €900)	Standard Pricing
Conference + Workshop	€2,198	€3,098
Conference Only	€1,899	€2,699
Workshop Only	€399	€499

Academic Pricing	Register & Pay By Friday 25 October (Save Up To €900)	Standard Pricing
Conference + Workshop	€1,698	€2,598
Conference Only	€1,499	€2,299
Workshop Only	€299	€399

Team Discounts*

- 10% discount – 3 delegates
- 15% discount – 4 delegates
- 20% discount – 5+ delegates

Please note that discounts are only valid when three or more delegates from one company book and pay at the same time.

Discounts cannot be used in conjunction with any other offer and are only eligible on industry pricing. Only one discount offer may be applied to the current pricing rate.

Contact:
register@hansonwade.com

VENUE

Hilton Vienna Plaza

Schottenring 11, 1010 Wien, Austria

For further information or assistance, please visit

https://www3.hilton.com/en/hotels/austria/hilton-vienna-plaza-VIEPWTW/index.html?WT.mc_id=zELWAKNOEMEA1HI2DMH3LocalSearch4DGGenericx6VIEPWTW

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Hanson Wade reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers. Hanson Wade is not responsible for any loss or damage, or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade, Suite A, 6 Honduras Street, London EC1Y 0TH

Code: 16119